Interaction of the neu/p185 and EGF receptor tyrosine kinases: Implications for cellular transformation and tumor therapy

作者: William C. Dougall , Xiaolan Qian , Mark I. Greene

DOI: 10.1002/JCB.240530108

关键词:

摘要: Growth factor receptors such as the epidermal growth receptor (EGFR) and p185c-neu protein serve vital roles in transduction of differentiation, developmental, or mitogenic signaling within normal cells. Two methods analysis suggest that inappropriately high expression either tyrosine kinase promotes malignant transformation. First, data from vitro experiments indicate overexpression EGFR (or human homolog c-erbB-2) transforms cell-lines. Second, primary tumors tumor cell-lines derived many epithelial tissues (breast, stomach, ovary, pancreas) show gene amplification elevated levels. The physical functional interaction leads to formation a highly active, heterodimeric complex which synergistically activates cellular Anti-receptor antibodies have shown potential utility for down modulation these cell-surface proteins suppression phenotype. Design organic antibody “mimetics” based on structure antireceptor may provide useful therapies biological reagents affect function.

参考文章(52)
Carlos Cordon-Cardo, Michael F. Press, Dennis J. Slamon, Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene. ,vol. 5, pp. 953- 962 ,(1990)
Lemoine Nr, Gullick Wj, Plowman Gd, Selden C, Prigent Sa, Hughes Cm, Expression of the c-erbB-3 protein in normal human adult and fetal tissues. Oncogene. ,vol. 7, pp. 1273- 1278 ,(1992)
W.V. Williams, T. Kieber-Emmons, D.B. Weiner, D.H. Rubin, M.I. Greene, Contact residues and predicted structure of the reovirus type 3-receptor interaction. Journal of Biological Chemistry. ,vol. 266, pp. 9241- 9250 ,(1991) , 10.1016/S0021-9258(18)31576-X
T Spivak-Kroizman, D Rotin, D Pinchasi, A Ullrich, J Schlessinger, I Lax, Heterodimerization of c-erbB2 with different epidermal growth factor receptor mutants elicits stimulatory or inhibitory responses Journal of Biological Chemistry. ,vol. 267, pp. 8056- 8063 ,(1992) , 10.1016/S0021-9258(18)42407-6
I.M. Harwerth, W Wels, B.M. Marte, N.E. Hynes, Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists Journal of Biological Chemistry. ,vol. 267, pp. 15160- 15167 ,(1992) , 10.1016/S0021-9258(18)42160-6
R Ben-Levy, E Peles, R Goldman-Michael, Y Yarden, An oncogenic point mutation confers high affinity ligand binding to the neu receptor. Implications for the generation of site heterogeneity. Journal of Biological Chemistry. ,vol. 267, pp. 17304- 17313 ,(1992) , 10.1016/S0021-9258(18)41926-6
G Gasparini, W J Gullick, P Bevilacqua, J R Sainsbury, S Meli, P Boracchi, A Testolin, G La Malfa, F Pozza, Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features. Journal of Clinical Oncology. ,vol. 10, pp. 686- 695 ,(1992) , 10.1200/JCO.1992.10.5.686
P P Di Fiore, O Segatto, F Lonardo, F Fazioli, J H Pierce, S A Aaronson, The carboxy-terminal domains of erbB-2 and epidermal growth factor receptor exert different regulatory effects on intrinsic receptor tyrosine kinase function and transforming activity. Molecular and Cellular Biology. ,vol. 10, pp. 2749- 2756 ,(1990) , 10.1128/MCB.10.6.2749